Abstract
The issue of the risk-benefit assessment of cyclooxygenase-2 (COX-2) inhibitors, as compared to traditional non-steroidal anti-inflammatory drugs (tNSAIDs), is far from being resolved. These compounds need to be carefully re-evaluated in order to avoid hasty conclusions, as it happened when COX-2 inhibitors were introduced into clinical practice. Several arguments support the concept, that COX-2 inhibitors remain a valuable therapeutic option at least for selected patients.
MeSH terms
-
Analgesics / adverse effects*
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Arthritis / drug therapy
-
Aspirin / therapeutic use
-
Cardiovascular Diseases / chemically induced
-
Clopidogrel
-
Cyclooxygenase 2 Inhibitors / adverse effects*
-
Drug Interactions
-
Drug Therapy, Combination
-
Gastrointestinal Hemorrhage / chemically induced
-
Humans
-
Patient Selection
-
Platelet Aggregation Inhibitors / therapeutic use
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Thrombosis / chemically induced*
-
Thrombosis / prevention & control
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
Substances
-
Analgesics
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase 2 Inhibitors
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine
-
Aspirin